Indoco Remedies Reports Declining Financial Performance in Q3 FY24-25 Results

Indoco Remedies, a small-cap player in the pharmaceuticals and drugs industry, has reported its financial results for the third quarter of FY24-25, declared on January 21, 2025. The company's recent performance has prompted an adjustment in its evaluation, with its score reflecting a shift to -29 from -38 over the past three months.
The financial indicators present a concerning picture for Indoco Remedies. The operating profit to interest ratio has reached a low of 0.75 times, suggesting challenges in managing interest obligations. Profit Before Tax (PBT) has fallen to Rs -32.80 crore, marking a significant decline compared to the average PBT of Rs 9.65 crore from the previous four quarters. Likewise, Profit After Tax (PAT) is reported at Rs -27.38 crore, a notable drop from an average of Rs 6.13 crore.

Net sales have also decreased, now at Rs 410.55 crore, which is a decline of 7.4% from the previous quarter's average. The operating profit margin has contracted to 2.93%, indicating a reduction in operational efficiency. Overall, these financial metrics highlight a challenging period for Indoco Remedies.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.